Search

Displaying results 1781 - 1790 of 8517 in total
  1. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. … It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.

  2. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. … In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine.

  3. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.

  4. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    Dexamethasone was therefore recommended as a life-saving treatment for COVID-19 patients experiencing severe respiratory symptoms.[L14318] … [L10701] Recently, dexamethasone has been a drug of interest in the treatment of COVID-19.

  5. Drug

    Serine

    go.drugbank.com/drugs/DB00133
    ApprovedInvestigationalNutraceutical

    A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.

  6. Drug

    Ebastine

    go.drugbank.com/drugs/DB11742
    ApprovedInvestigationalWithdrawn

    Ebastine has been investigated for the treatment of Urticaria.

  7. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...

  8. Drug

    Celecoxib

    go.drugbank.com/drugs/DB00482
    ApprovedInvestigational

    [A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. … [L7604] Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies

  9. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    [L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]

  10. Drug

    Atracurium besylate

    go.drugbank.com/drugs/DB00732
    Approved

    A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate no...